Drug Type Small molecule drug |
Synonyms 7,8-dihydroxyflayone derivative (Shanghai Braegen Pharmaceutical), BRAD R13, BRAD-R13 + [2] |
Target |
Action stimulants |
Mechanism TrkB stimulants(Neurotrophic tyrosine kinase receptor type 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 1 | United States | 01 May 2019 | |
Schizophrenia | Preclinical | China | 29 Aug 2024 | |
Amyotrophic Lateral Sclerosis | Preclinical | China | 11 May 2024 | |
ischemic brain injury | Preclinical | China | 11 May 2024 | |
Acute Ischemic Stroke | Preclinical | - | - | |
Depressive Disorder | Preclinical | China | - | |
Parkinson Disease | Preclinical | China | - |